Minerva Neurosciences (NERV) vs Organogenesis (ORGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Organogenesis (ORGO) over the past year, losing 49.2% versus a loss of 86.2%. Over five years, NERV leads with a -76.4% price change compared with -92.2% for ORGO. Organogenesis is the larger company by market cap ($100.2 million vs $99.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | ORGO |
|---|---|---|
| Share price | $2.00 | $0.7716 |
| Market cap | $99.67M | $100.16M |
| 1-day change | -5.66% | -2.23% |
| YTD return | -50.25% | -85.10% |
| 1-year return | -49.24% | -86.20% |
| 5-year return | -76.42% | -92.25% |
| EPS (TTM) | $-33.83 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $564.17M |
| Revenue growth (YoY) | — | +17.04% |
| Net income (latest FY) | $-293.42M | $37.03M |
| Operating margin | — | 7.92% |
| Net margin | — | 6.56% |
| 52-week high | $8.80 | $5.91 |
| 52-week low | $1.96 | $0.73 |
| Distance from 52-week high | -77.27% | -86.93% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +416.50% | — |
| Average volume | 164.71K | 850.26K |
| Shares outstanding | 49.84M | 129.80M |
| Employees | 7 | 854 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed ORGO by 37.0 percentage points over the past year.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Organogenesis
ORGO stock →Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.
Health Care · Biotechnology: Pharmaceutical Preparations · 854 employees
NERV vs ORGO FAQ
Which is bigger, Minerva Neurosciences or Organogenesis?
Organogenesis (ORGO) is larger, with a market capitalization of $100.16M compared with $99.67M for Minerva Neurosciences (NERV).
Which stock has performed better over the past year, NERV or ORGO?
NERV returned -49.24% over the past 12 months, compared with -86.20% for ORGO (price return, excluding dividends). Past performance does not predict future results.
Are Minerva Neurosciences and Organogenesis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.